CD37 and B-cell chronic lymphocytic leukemia: Strikingly, DuoHexaBody-CD37 induced superior CDC activity in all patient-derived CLL samples compared to either the single mAbs or the combination, which was most apparent in the refractory CLL sample (Fig. 3a–d).